You need to login...
If you are not registered...
| Subscribe to Templeton Apus - Universal: | For a free, non-obligation trial: |
|
or call us on: +44 (0)20 7769 6707 or email: apus@templetonapus.com |
|
Most viewed
- 1. Exclusive: Chilean regulator preps sweeping Atacama review as it abandons SQM legal battle
- 2. Evogene: Hidden Gems Of Computational Predictive Biology, Part 1 Of 4 (Biomica, Microbiome Therapeutics)
- 3. Evogene Reports Second Quarter 2020 Financial Results
- 4. Seres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock
- 5. Novo Holdings establishes new Asian life sciences investment platform in Singapore – Amit Kakar to become Head of Asia
- 6. A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
- 7. A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
- 8. Alimera Sciences Signs Distribution Agreement With Nordic Prime to Expand International Sales of ILUVIEN Into Nordic Countries
- 9. Iomab-ACT: A Pilot Study of 131-I Apamistamab (Iomab-B) Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
- 10. Celleron licenses cancer drug emactuzumab from Roche
Last updated at 8:14 GMT
Sectors & Industries
© Copyright 2020 Templeton Apus. All rights reserved.
Made with 
and
in the EU & the UK
and
in the EU & the UK